Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$423.33 USD

423.33
206,725

+5.48 (1.31%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $424.08 +0.75 (0.18%) 5:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Align Technology (ALGN) Beats on Earnings and Revenues in Q1

by Zacks Equity Research

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

    Zacks Equity Research

    Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

    by Zacks Equity Research

    Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

      Zacks Equity Research

      Chemed (CHE) Hits a 52-Week High, Can the Run Continue?

      by Zacks Equity Research

      Chemed Corporation is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for CHE for clues.

        Zacks Equity Research

        CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow

        by Zacks Equity Research

        CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.

          Zacks Equity Research

          Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4

          by Zacks Equity Research

          Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.

            Zacks Equity Research

            ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth

            by Zacks Equity Research

            ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.

              Zacks Equity Research

              Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1

              by Zacks Equity Research

              Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

                Zacks Equity Research

                GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown

                by Zacks Equity Research

                GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.

                  Zacks Equity Research

                  Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid

                  by Zacks Equity Research

                  Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.

                    Zacks Equity Research

                    Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates

                    by Zacks Equity Research

                    Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.

                      Zacks Equity Research

                      CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance

                      by Zacks Equity Research

                      CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.

                        Zacks Equity Research

                        Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View

                        by Zacks Equity Research

                        Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.

                          Zacks Equity Research

                          Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop

                          by Zacks Equity Research

                          Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.

                            Zacks Equity Research

                            Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                            by Zacks Equity Research

                            Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                              Zacks Equity Research

                              Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View

                              by Zacks Equity Research

                              Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.

                                Zacks Equity Research

                                MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE

                                by Zacks Equity Research

                                On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.

                                  Zacks Equity Research

                                  Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View

                                  by Zacks Equity Research

                                  Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.

                                    Zacks Equity Research

                                    Will Envision Healthcare's Growth Strategies Help the Stock?

                                    by Zacks Equity Research

                                    Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.

                                      Zacks Equity Research

                                      New Year to Bring Back MedTech Tax, 3 Stocks Unfazed

                                      by Zacks Equity Research

                                      Investors are apprehensive about the re-enactment of MedTech Tax and related concerns, despite raking in returns from other sectors.

                                        Zacks Equity Research

                                        4 Reasons Why Envision Healthcare (EVHC) Looks Dull

                                        by Zacks Equity Research

                                        Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.

                                          Zacks Equity Research

                                          Zimmer Biomet Strong on Positive Data From PROGRESS II Study

                                          by Zacks Equity Research

                                          Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.

                                            Zacks Equity Research

                                            Here's Why You Should Invest in Masimo (MASI) Right Now

                                            by Zacks Equity Research

                                            Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

                                              Zacks Equity Research

                                              Haemonetics Banks on Hospital Business, Competition Rife

                                              by Zacks Equity Research

                                              For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.

                                                Zacks Equity Research

                                                Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                                by Zacks Equity Research

                                                Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                                  Tirthankar Chakraborty headshot

                                                  5 of the Best Efficient Stocks to Strengthen Your Portfolio

                                                  by Tirthankar Chakraborty

                                                  We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns